Literature DB >> 1599611

Protein toxin inhibitors of protein synthesis.

J P Perentesis1, S P Miller, J W Bodley.   

Abstract

Two classes of extremely toxic proteins kill eukaryotic cells by covalently modifying unique structural features of components that are essential for protein synthesis. Intoxication by these proteins results from the entry of a catalytic fragment into the cytoplasm. One class is typified by diphtheria toxin and Pseudomonas exotoxin A. The catalytic component of these toxins ADP-ribosylates and inactivates elongation factor 2 which is an essential participant in protein synthesis. This modification occurs at a unique post-translational histidine derivative, diphthamide, that is present in the ribosomal binding site of the elongation factor. The two toxins differ in their molecular organization but appear to possess identical reaction mechanisms and very similar active sites. The other class contains two types of toxins typified, respectively, by alpha-sarcin, a member of a family of fungal toxins, and ricin, a member of a group of closely related plant proteins collectively termed ribosome-inactivating proteins. The catalytic components of the two types of toxins in this second class inactivate the large ribosomal subunit through two different hydrolytic alterations of 23-28S RNA. alpha-Sarcin and its congeners act as a specific endonuclease whereas ricin and its congeners act as a specific N-glycosidase. These hydrolytic cleavages occur at a pair of adjacent nucleotides within a highly conserved sequence near the 3' terminus of 23-28S RNA. The covalent integrity of this region of RNA is essential to elongation factor-dependent ribosomal functions and is located within the ribosomal binding domain of these factors. Both of these classes of toxins are being employed as 'magic bullets' to eliminate pathological cells. By combining the catalytic component of these toxins with various cell targeting components, useful and specific anticancer and immunomodulatory agents have been created.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1599611

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  10 in total

1.  Iron starvation causes release from the group A streptococcus of the ADP-ribosylating protein called plasmin receptor or surface glyceraldehyde-3-phosphate-dehydrogenase.

Authors:  Z Eichenbaum; B D Green; J R Scott
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Partial characterization of a cell proliferation-inhibiting protein produced by Helicobacter pylori.

Authors:  U Knipp; S Birkholz; W Kaup; W Opferkuch
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

3.  Characterization of a Chinese hamster ovary cell mutant having a mutation in elongation factor-2.

Authors:  Pradeep K Gupta; Shihui Liu; Stephen H Leppla
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 4.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

5.  A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.

Authors:  G C MacDonald; M Rasamoelisolo; J Entwistle; W Cuthbert; M Kowalski; Maureen A Spearman; N Glover
Journal:  Med Oncol       Date:  2008-10-28       Impact factor: 3.064

6.  The diphthamide modification on elongation factor-2 renders mammalian cells resistant to ricin.

Authors:  Pradeep K Gupta; Shihui Liu; Mariska P Batavia; Stephen H Leppla
Journal:  Cell Microbiol       Date:  2008-05-05       Impact factor: 3.715

7.  Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans.

Authors:  J M Domínguez; J J Martín
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 8.  Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins.

Authors:  Meiqi Zeng; Manyin Zheng; Desheng Lu; Jun Wang; Wenqi Jiang; Ou Sha
Journal:  Chin J Cancer       Date:  2015-07-17

9.  A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

Authors:  Glen C MacDonald; Michèle Rasamoelisolo; Joycelyn Entwistle; Jeannick Cizeau; Denis Bosc; Wendy Cuthbert; Mark Kowalski; Maureen Spearman; Nick Glover
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Butylated hydroxytoluene and Butylated hydroxyanisole induced cyto-genotoxicity in root cells of Allium cepa L.

Authors:  Himadri Pandey; Sanjay Kumar
Journal:  Heliyon       Date:  2021-05-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.